Middle East & Africa Biopharmaceutical Cmo And Cro Market Size & Outlook
Middle East & Africa biopharmaceutical cmo and cro market, 2017-2030 (US$M)
Related Markets
MEA biopharmaceutical cmo and cro market highlights
- The MEA biopharmaceutical cmo and cro market generated a revenue of USD 550.0 million in 2021.
- The market is expected to grow at a CAGR of 11% from 2022 to 2030.
- In terms of segment, mammalian was the largest revenue generating source in 2021.
- Non-mammalian is the most lucrative source segment registering the fastest growth during the forecast period.
- Country-wise, South Africa is expected to register the highest CAGR from 2022 to 2030.
MEA data book summary
| Market revenue in 2021 | USD 550.0 million |
| Market revenue in 2030 | USD 1,410.0 million |
| Growth rate | 11% (CAGR from 2021 to 2030) |
| Largest segment | Mammalian |
| Fastest growing segment | Non-mammalian |
| Historical data covered | 2017 - 2020 |
| Base year for estimation | 2021 |
| Forecast period covered | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Mammalian, Non-mammalian |
| Key market players worldwide | Boehringer Ingelheim, Lonza Group Ltd, Innovent Biologics Inc, Rentschler Biopharma SE, JRS Pharma, AGC Inc, Probiogen, FUJIFILM Holdings Corp, Toyobo Co Ltd, Samsung BioLogics, Thermo Fisher Scientific Inc, R1 RCM Inc, WuXi Biologics (Cayman) Inc, AbbVie Inc, Binex, Charles River Laboratories International Inc, Icon PLC, PAREXEL, Labcorp Holdings Inc |
Other key industry trends
- In terms of revenue, MEA region accounted for 1.9% of the global biopharmaceutical cmo and cro market in 2021.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Latin America is the fastest growing regional market and is projected to reach USD 1,536.2 million by 2030.
Key Regions: U.S. , Brazil , South Africa , Canada , Germany
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Biopharmaceutical CMO And CRO Market Scope
Biopharmaceutical CMO And CRO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Middle East & Africa biopharmaceutical cmo and cro market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biopharmaceutical cmo and cro market will help companies and investors design strategic landscapes.
Mammalian was the largest segment with a revenue share of 59.56% in 2021. Horizon Databook has segmented the Middle East & Africa biopharmaceutical cmo and cro market based on mammalian, non-mammalian covering the revenue growth of each sub-segment from 2017 to 2030.
Outsourcing of manufacturing and research operations in MEA offers advantages such as costeffectiveness, better infrastructure, and excellent healthcare facilities.
Government incentive schemes to increase domestic production, rising healthcare needs, and presence of brand-friendly environment are boosting the biopharmaceutical industry in the region. This is expected to increase outsourcing of biopharmaceutical activities to CMOs and CROs based in MEA.
Reasons to subscribe to Middle East & Africa biopharmaceutical cmo and cro market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Middle East & Africa biopharmaceutical cmo and cro market databook
-
Our clientele includes a mix of biopharmaceutical cmo and cro market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa biopharmaceutical cmo and cro market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa biopharmaceutical cmo and cro market from 2017 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
MEA biopharmaceutical cmo and cro market size, by country, 2017-2030 (US$M)
Middle East & Africa Biopharmaceutical CMO And CRO Market Outlook Share, 2021 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
